BMS allocates $173M for RayzeBio’s second radiopharma plant in Indiana
Bristol Myers Squibb, via its RayzeBio unit, plans to invest $173 million in a new radiopharmaceutical manufacturing facility in Whitestown, Indiana. The company expects the two Indiana sites to add 100 jobs by the end of 2029, with annual wages above $130,000, building on its prior $160 million Indianapolis plant and radiopharmaceutical expansion plans.